Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective evaluation of model-informed precision dosing for tacrolimus and mycophenolic acid in pediatric kidney disease
NL-OMON56572Completed
- Sponsor
- Radboud University Medical Center
- Start
- May 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tacrolimus and mycophenolic acid in chronic kidney disease (CKD), sponsored by Radboud University Medical Center. Primary endpoints: Bias and precision of MIPD predictions, Confidence intervals for prediction metrics and 2 more. Started May 2024; status: completed.
02
Drugs
tacrolimusmycophenolic acid
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON56572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56572.